Hotel Chocolat sees acceleration in sales

0

Hotel Chocolat has posted strong sales and saw revenues increase 37% year-on-year.

Sales were strong all over the world, with 128% growth in the US and 131% growth in Japan. In Japan the customer database has grown by 1000%.

“These results demonstrate that the Hotel Chocolat brand is connecting with more customers, as we invest continually in new product creativity, driving growth across channels and categories, and in our ‘gentle farming’ initiative supporting cacao-farming families,” said Angus Thirlwell, Co-Founder and Chief Executive Officer.

“All of our six growth drivers are behind the acceleration in sales: Velvetiser in-home drinks system, VIP Loyalty rewards, and Digital, whilst the USA, Global Wholesale, and the Japan joint venture are finding the formula for sustained growth, and our UK domestic market still has huge potential.”

Hugo Boss posts strong Q4

0

Hugo Boss is almost back at pre-pandemic levels after strong fourth-quarter earnings.

Revenues jumped 43% in 2021 to €2.79bn (£2.33bn), which is just 1% below pre-pandemic levels. Fourth quarter sales jumped 55% to €906.

The group has raised its outlook for sales and expects them to grow 40%.

“2021 was a highly successful year for Hugo Boss. We strongly accelerated our sales and earnings development throughout the year and also made first great strides in executing our new ‘CLAIM 5’ growth strategy,” said chief executive, Daniel Grider.

“The upcoming weeks will see further important milestones, with the introduction of our new branding and the launch of the biggest Boss and Hugo marketing campaigns in our Company’s history. Based on these exciting initiatives, we will further drive brand relevancy in 2022.”

Marshalls revenues jump

0

Marshalls reported strong results this morning as revenues jumped 26% to £589m.

Compared to the same period in 2019, revenues were up 11%.

“The Group has strong supplier relationships and our centralised procurement team continue to actively manage the supply chain to create flexibility and reduce risk,” said the group in a trading statement.

“Underlying market demand continues to be strong and the business has been experiencing trading volumes that are outperforming the Construction Products Association’s growth forecasts.”

Expectations for the year ending 31 December 2021 have been increased slightly.

New standard listing: Genflow Biosciences seeks to hold back ageing

Genflow Biosciences is developing treatments that reduce or delay age-related diseases. The company is London-based, but the research and development is undertaken in Belgium. There is already a compound in pre-clinical trials.
Chief executive Dr Eric Leire is the founder of the business and still owns more than two-fifths of the company. He has two decades of experience in cell and gene therapies.
The share price opened at 9.25p and ended the day at 11.5p. There were 2.16 million shares traded.
This is an early-stage company, and it will be back for more cash in the future. The shares are ful...

CentralNic growth accelerates

Domain name and online marketing services provider CentralNic (LON: CNIC) is going from strength to strength and growth is accelerating.
The fourth quarter organic revenue growth was substantial, and the 2021 full year growth was 37%, which is better than expected and higher than the 29% growth in the first nine months of 2021. The full year revenue estimate of $410m is what Zeus was previously forecasting for 2022.
CentralNic continues to be an international consolidator of the internet domain registry sector, while the online marketing division provides high-quality advertising traffic witho...

Still some way to go for DP Poland profit

Cost increases mean that the move towards profitability at pizza company DP Poland (LON: DPP) is slower than expected. Like-for-like sales growth is being achieved but it has been tough.
Year-on-year like-for-like fourth quarter growth in system sales was 15.6%, which followed a flat third quarter. They were also higher than for the fourth quarter of 2019. However, even though dine-in sales recovered despite the Covid restrictions they were still lower than in the fourth quarter of 2019. There are still restrictions holding back growth.
There was no government support for the restaurant sector...

Applied Graphene Materials: Crap-theme to Eco-Graphene

Applied Graphene Materials (LSE: AGM) 22.5p Mkt Cap £14m.  Since floating at 155p over 10 years ago the producer of speciality graphene nanoplatelets has recently had a couple of product development news items. 
A ground-breaking new range of eco-friendly graphene will improve sustainability of its client’s product formulations of paints, coatings, and composite materials.  Most recently England’s Environmental Agency, announced the successful completion of an 18month trial of its harsh environmental anticorrosion ‘paints’ used on a coastal flood defence. It is, also anticipated that there wil...

A guide to investing in the Enterprise Investment Scheme – for HNW investors

by Mark Bower-Easton, Business Development Manager, Oxford Capital

The Enterprise Investment Schemes (EIS) is a government initiative, created by John Major’s government in 1994, and has continued to receive the full backing of parliament, regardless of which side of the political spectrum is in power. EIS is designed to boost the economy and jobs market by offering tax incentives to those looking to create new businesses, and people looking to invest into those businesses.  To download Oxford Capital’s Guide to EIS, click here.

In the early days of EIS, if you wanted to take advantage of the tax reliefs you would need to find your own investment opportunities and deal with all of the administrative requirements that came with it. In 1999, Oxford Capital was founded, and a new way to utilise EIS tax reliefs was pioneered – the EIS portfolio. Oxford Capital removed the burden of private investors needing to source and undertake due diligence on the companies, and provided a portfolio of pre-sourced, vetted companies that private investors could invest in to. This model has since been adopted by every other venture capital house in the UK, in one form or another.

Before we talk about the multitude of tax reliefs available to private investors, and how these can be utilised by high-net worth investors in the real world, it is important that we talk about risk. The underlying assets within an EIS portfolio are high risk. They are early-stage, unquoted companies, that might succeed, but may also suffer total failure. Due to the shares being unquoted, there is no market to trade them, so liquidity will be non-existent until the point that the shares held can be sold, typically via trade sale, IPO or management buyout. Recently we have made some partial sales in our businesses, aimed at crystalising some of the growth we have achieved, and returning some funds to our investors, but this isn’t something that will happen on a regular basis. 

In order to invest in EIS you need to be comfortable with the risk levels present. You also need capacity for loss –if your investment was to lose a significant amount of value, that it wouldn’t materially affect your standard of living. You also need to be comfortable with the lack of liquidity, or access to your money for at least 5-7 years. If you are not comfortable with one or more of the three areas of risk just mentioned, then you should not be considering EIS as a viable investment option.

However, for those who are comfortable with the risk, the capacity for loss, and lack of liquidity, an EIS can be a compelling investment option. Investors will gain access to an asset class that is otherwise unavailable and will be investing into some of the most exciting companies the UK has to offer. On top of that, investors will be able to take advantage of a multitude of tax reliefs, which are summarised below, which can help to make effective tax planning choices.

Income Tax Relief

For every £1 that is invested in to an EIS, 30p income tax relief will be given. This can be offset against your income tax bill either in the current tax year, or if not previously utilised, the previous tax year. When I previously worked as an adviser, I had a lot of clients who would place their annual bonuses in to EIS in order to reduce the burden of income tax on it as much as possible.

EIS can also be a great option for business owners – particularly those who are looking to extract profits but have already maxed out their annual pension contributions or hit their lifetime allowance. Typically, business owners will pay themselves a small salary, usually the same figure as the income tax nil-rate-band, and pay themselves the rest as dividends, as dividend rates are lower than earned income rates. Regardless of whether their income is earned income or dividend income, the income tax relief generated by an EIS can be used to offset most of the liability.

It is important to note that Income Tax Relief is given at the point EIS3 certificates are provided to HMRC via an annual tax return – not at the point the initial investment is made. Each company in an investor’s portfolio will receive an EIS3 certificate. It should also be noted that the minimum holding period to maintain income tax relief is three years. If the shares are sold before this time has elapsed, HMRC will claw back the income tax relief already given.

Capital Tax Free Gains

When the time comes to sell EIS shares, any growth generated will be totally free from Capital Gains Tax. Early stage companies have the potential for significant growth, so the tax saving of an EIS share compared to a share listed on a quoted stock exchange (and not held within a tax-free wrapper, such as an ISA) will be very significant.

Again, this tax relief is subject to the minimum three-year holding period, and income tax relief must have already been claimed.

Capital Gains Tax Deferral Relief

Perhaps you have a holiday home, a buy to let property, or a portfolio of shares that you are looking to sell but are reticent to do so due to having to pay a large CGT bill upon sale. With an EIS it is possible to defer a capital gain indefinitely, by investing the realised gain in to an EIS. All the while the EIS shares are held, CGT will not be payable. This can be a very effective solution for estate planning, as CGT is the only tax in the UK where your liability dies with you. 

An example of how this might work in practice would be an investor with a large portfolio of shares, and also a large IHT liability. If the investor did nothing, at the point he or she passed away, their beneficiaries would not have to pay the CGT bill. However, the total value of the shares would be added to their estate for IHT purposes, and tax would be payable at 40%. By crystallising the gain and investing it in to EIS, you are deferring the capital gain, but also eliminating IHT, assuming he or she lives a further two years from the point of purchase of the EIS shares (more on IHT benefits below).

To qualify for CGT deferral relief, the reinvestment in to EIS needs to be made no earlier than 12 months prior to, or three years after the original gain was made.

In this scenario, if you sell your EIS shares, the CGT liability will become payable again. However, you can simply reinvest in to a new EIS qualifying investment and continue to defer. If at some point you decide to pay the CGT liability, it is worth noting that the liability will be taxed at the relevant rate at that time, not at the point at which the CGT liability originally arose.

Business Relief

All EIS shares qualify for Business Relief. Put simply, this means that after a holding period of two years, the value of the EIS shares are not liable for IHT, assuming they are still held upon death. 

Business Investment Relief

EIS shares are an allowable asset under BIR rules. This enables UK resident, non-domiciled investors to invest using offshore funds. BIR allows this money to be utilised without them incurring the remittance tax charge, which typically puts off these investors from using offshore funds. When a company exits, the investor can choose to take the money back offshore, or alternatively can bring the capital gain element into the UK without any liability to tax.

Loss Relief

As mentioned earlier, EIS investing is high risk. However, there is a safety net in place. The UK Government is effectively underwriting a significant proportion of the downside risk by giving every investor loss relief. 

If the share value drops to zero (i.e. the company fails), or the shares are sold for less than the original amount invested, then an investor can claim loss relief, which will enable them to offset a loss made on an EIS company against either their CGT bill or income tax bill, depending on which best suits their situation. The amount of loss relief provided depends on your income tax rate, so if you are an additional rate taxpayer, the maximum loss you could incur by investing in to EIS is 38.5% of your capital. Click here for our guide to loss relief.

To qualify, the share needs to fall below what is known as the “effective cost”. Simply put, the amount invested minus the amount claimed in initial income tax relief on that share, so usually 70% of the gross cost, as the initial income tax relief figure is 30%.

Loss relief is based on each company in a portfolio, not on the portfolio overall. So, even if your EIS portfolio is showing a 3x return, if there are one of two failed companies in there, it is perfectly acceptable to claim loss relief on these.

In summary, an EIS, can be a great way to diversify an existing investment portfolio by adding a new asset class, and providing access to companies unavailable elsewhere. The multitude of tax benefits can also play a significant part in creating an efficient tax strategy if you are looking to reduce your income tax bill, defer a CGT bill, or reduce your IHT liability – as long as you are comfortable with the risks associated with early-stage investing.

For more information on the Oxford Capital Growth EIS, visit our website here, to download our Guide to EIS investing, click here.

HSBC launches £500m fund for Green UK SMEs

HSBC have launched a £500m fund with the aim of providing loans to UK businesses using the funds to invest in green activities.

To qualify, businesses must have a turnover of less than £25m and prove they will meet HSBC’s green eligibility criteria. HSBC’s criteria includes activities such as Energy from Waste, Solar, Heat Pumps and Green constuction activities.

HSBC will pay 1% cashback on loans that start at £1,000.

“I am delighted to announce to the launch of HSBC UK’s £500m Green SME Fund,” said Ian Stuart, CEO HSBC UK.

“Companies of all sizes and sectors have a role to play in the journey to net zero, however the sustainable finance market has been predominately focused on larger corporations. It’s critical that access to funds isn’t a barrier for small and medium sized businesses working to achieve lower carbon emissions.’

“We want to help businesses seize the opportunities and growth potential that environmental sustainability offers and the fund, along with our new and expanding suite of tools and resources, will make it easier for small businesses to take practical steps to cut their emissions and help their customers to cut theirs too.”

GlaxoSmithKline shares surge as Unilever eyes their consumer business

GlaxoSmithKline shares surged over 4% in early trade on Monday as the Pharmaceutical Group rejected a $50bn offer from Unilever for their consumer business.

GlaxoSmithKline said the offer ‘fundamentally undervalued’ the unit which contains brands such as Panadol and Sensodyne.

“GlaxoSmithKline’s share price has jumped on the news as Unilever’s actions effectively fire the starting gun for a bid war for the consumer goods unit. Nestle could be interested, so too private equity,” said Russ Mould, investment director at AJ Bell.

“Unilever looks to be bidding for the unit because it needs to inject some excitement into its business, having recently disappointed with sales and profit margins.”

“This really is a Marmite situation for GlaxoSmithKline’s shareholders – they’re either hoping for a quick return now through a sale or better returns in the future through the planned demerger.”

While Glaxo shares jumped, Unilever shares plummeted on the news. Unilever shares had crashed 6.5% at the time of writing on Monday morning on fears Unilever were set to overpay for the unit as they scrambled to implement their new strategy.

“The market has given a thumbs down to news that Unilever has bid for GlaxoSmithKline’s consumer goods division. The negative share price reaction probably reflects investors’ fears that Unilever is going to come back with a higher offer and potentially pay too much,” said Russ Mould.

Unilever have recently alluded to a new strategy that focuses on their Health, Beauty and Hygiene units and the attraction of GSK’s consumer business will mean Glaxo is in the position to squeeze Unilever on the valuation.

‘Based on Unilever’s new strategic direction, which includes increased focus on growth in the Health, Beauty and Hygiene segments, there could be another offer in the pipeline,” said Laura Hoy, Equity Analyst at Hargreaves Lansdown.

“The group says it will pounce on acquisition opportunities within the space, and they don’t get much more appealing than this one. With Unilever’s Tea business expected to bring in upwards pf £4bn when it’s sold later this year, management might have the firepower to sweeten the deal. Glaxo’s healthcare business comes with a hefty debt pile, though, which could keep a lid on the price Unilever—or any other suitors—are willing to pay.”